Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Circulating CD34+ counts and apheresis planning.

R L Auer1, P Holtom, H Smith

  • 1Department of Haematology, Birmingham Heartlands Hospital, U.K.

Hematological Oncology
|March 5, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mitoxantrone, Etoposide and Prednisolone-a Novel Combination in The Treatment of Relapsed and Refractory Lymphoma.

Leukemia & lymphoma·2016
Same author

Primary care management of early stage chronic lymphocytic leukaemia is safe and effective.

QJM : monthly journal of the Association of Physicians·2015
Same author

Evidence for a GVL effect following reduced-intensity allo-SCT in ALL: a British Society of Blood and Marrow Transplantation study.

Bone marrow transplantation·2013
Same author

The incidence of raised procoagulant factors and hyperhomocysteinaemia in Chinese patients with chronic venous insufficiency.

European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery·2010
Same author

Does reduced-intensity allogeneic transplantation confer a survival advantage to patients with poor prognosis chronic lymphocytic leukaemia? A case-control retrospective analysis.

Annals of oncology : official journal of the European Society for Medical Oncology·2009
Same author

Survival from adult leukaemia in England and Wales up to 2001.

British journal of cancer·2008
Same journal

Integrated Glycoproteomics Identifies Dynamic IgA1 N-Glycosylation and FUT8 as a Functional Mediator in Multiple Myeloma.

Hematological oncology·2026
Same journal

Sustained Complete Response in Refractory Idiopathic Multicentric Castleman Disease Following a Single CD19 CAR T-Cell Infusion: A Case Report With Mechanistic Insight.

Hematological oncology·2026
Same journal

Efficacy and Safety of Novel-Agent-Based Front-Line Therapy in Older Adults Aged ≥ 60 Years With Classic Hodgkin Lymphoma: A Systematic Review and Meta-Analysis.

Hematological oncology·2026
Same journal

Extracorporeal Cytokine Hemadsorption for the Treatment of Severe Steroid Refractory Cytokine Release Syndrome Secondary to T-Cell Immunotherapy for B-Cell Malignancies: A Case Series.

Hematological oncology·2026
Same journal

Glofitamab Induces Complete Responses in Relapsed and Refractory Primary Central Nervous System Lymphoma.

Hematological oncology·2026
Same journal

Impact of U2AF1 Pathogenic Variants on Prognosis of Myelodysplastic Neoplasms With RUNX1 Mutation.

Hematological oncology·2026
See all related articles

Peripheral blood CD34+ cell counts accurately predict apheresis yield and procedure numbers for progenitor cell transplantation. This finding aids in optimizing cell collection and planning apheresis services for better patient outcomes.

Area of Science:

  • Hematology
  • Transplantation Immunology
  • Cellular Therapy

Background:

  • Peripheral blood progenitor cell (PBPC) transplantation success relies on adequate cell collection.
  • Current methods using white blood cell (WBC) count to initiate apheresis do not reliably predict CD34+ cell yield or required procedures.

Purpose of the Study:

  • To evaluate the predictive value of peripheral blood CD34+ cell counts for apheresis yield.
  • To determine if peripheral CD34+ counts can predict the number of apheresis procedures needed to achieve target CD34+ cell doses.

Main Methods:

  • Prospective collection of peripheral blood and PBPC harvest data over 8 months.
  • Performance of CD34+ cell counts on peripheral blood and apheresis products.
  • Regression analysis to correlate peripheral CD34+ counts with apheresis yield and procedure requirements.

Related Experiment Videos

Main Results:

  • A strong, significant correlation was found between peripheral blood CD34+ cell count and the yield of CD34+ cells in the apheresis product.
  • Peripheral CD34+ counts demonstrated a weaker correlation with WBC counts for predicting apheresis product quality.
  • A peripheral CD34+ count ≥ 62 x 10^6/L predicts successful harvest in one apheresis; ≥ 40 x 10^6/L suggests two procedures may be needed.

Conclusions:

  • Peripheral blood CD34+ cell counts are superior to WBC counts for predicting apheresis yield.
  • CD34+ cell counts enable accurate prediction of apheresis requirements, improving service planning.
  • Implementing peripheral CD34+ count thresholds optimizes PBPC collection and resource allocation for transplantation.